Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 6/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | COMT | P21964 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 2/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.31 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3744556 | 0.68 | IDO1 (0.50) | IDO1ENPP2ALDH1A1COMTKDM4E | |
| SCHEMBL2721372 | 0.60 | IDO1 (0.60) | IDO1ENPP2ALDH1A1GAAKDM4E | |
| SCHEMBL11683834 | 0.55 | IDO1 (1.00) | IDO1ENPP2ALDH1A1GAAKDM4E | |
| SCHEMBL3180547 | 0.55 | ALDH1A1 (0.52) | IDO1ENPP2ALDH1A1GAAKDM4E | |
| SCHEMBL971897 | 0.55 | IDO1 (0.61) | IDO1ALDH1A1PIM1CSNK2BCSNK2A1 | |
| SCHEMBL12469918 | 0.55 | IDO1 (0.35) | IDO1ENPP2COMTKDM4ECYP3A4 | |
| SCHEMBL15681354 | 0.54 | IDO1 (0.38) | IDO1ENPP2KDM4ECYP3A4 | |
| SCHEMBL15926108 | 0.53 | CCR1 (0.57) | IDO1ENPP2ALDH1A1KDM4E | |
| SCHEMBL5820691 | 0.52 | IDO1 (0.53) | IDO1ENPP2GAAKDM4ECYP3A4 | |
| SCHEMBL3378014 | 0.52 | MKNK1 (0.46) | IDO1ENPP2PIM1CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1444211-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2009-01-21 | — | — | EP | disclosed |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB | 2007-04-19 | — | — | US | disclosed |
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
| EP-1444211-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | IDO1 783/4885ENPP2 2718/4885ALDH1A1 3334/4885 |
| US-20070088044-A1 | Quinazoline derivatives as antitumor agents | ERBB2, EGFR, ERBB4 | IDO1 1063/4885ENPP2 2927/4885ALDH1A1 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.